Evidence map›Paper›PMID 37154079›Full record

ArticleJournal of cellular and molecular medicine2023

Upregulation of MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 lncRNAs in non-functioning pituitary adenoma.

Mohammad Taheri, Arash Safarzadeh, Arefe Bahranian, Solat Eslami, Nader Akbari Dilmaghani, Soudeh Ghafouri-Fard, Guive Sharifi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Mohammad TaheriInstitute of Human Genetics, Jena University Hospital, Jena, Germany.ORCID 0000-0001-8381-0591
Arash SafarzadehPhytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Arefe BahranianSkull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Solat EslamiDepartment of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Nader Akbari DilmaghaniSkull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Soudeh Ghafouri-FardMen's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-0223-499X
Guive SharifiSkull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahid Beheshti University of Medical Sciences · IRJahrom University of Medical Sciences · IRJena University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) have been shown to be dysregulated in a variety of malignant and non-malignant lesions including non-functioning pituitary adenomas (NFPAs). In the current experimental study, we have selected six lncRNAs, namely MAPKAPK5-AS1, NUTM2B-AS1, ST7-AS1, LIFR-AS1, PXN-AS1 and URB1-AS1 to assess their expression in a cohort of Iranian patients with NFPA. MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 were shown to be over-expressed in NFPA tissues compared with control samples (Expression ratios (95% CI) = 10 (3.94-25.36), 11.22 (4.3-28.8) and 9.33 (4.12-21.12); p values < 0.0001, respectively). The depicted ROC curves showed the AUC values of 0.73, 0.80 and 0.73 for MAPKAPK5-AS1, PXN-AS1 and URB1-AS1, respectively. Relative expression level of PXN-AS1 was associated with tumour subtype (p value = 0.49). Besides, relative expression levels of MAPKAPK5-AS1 and LIFR-AS1 were associated with gender of patients (p values = 0.043 and 0.01, respectively). Cumulatively, the current study indicates the possible role of MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 lncRNAs in the pathogenesis of NFPAs.

Indexed as

Pituitary NeoplasmsRNA, Long NoncodingGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsIranNuclear ProteinsPaxillinProtein Serine-Threonine KinasesUp-RegulationIntracellular Signaling Peptides and ProteinsMAP-kinase-activated kinase 5Nuclear ProteinsPaxillinProtein Serine-Threonine KinasesPXN protein, humanRNA, Long NoncodingURB1 protein, humanlncRNAMAPKAPK5-AS1non-functioning pituitary adenomaPXN-AS1URB1-AS1

Identifiers

PMID37154079
PMCPMC10243150
OpenAlexW4375955766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.